Decision regret after external beam radiotherapy and high dose-rate brachytherapy boost for prostate cancer

• by Lars Haack, David Krug, Severin Rodler, Philipp Nuhn, Christof van der Horst, Christian Schulz, Olaf Wittenstein, Claudia Schmalz, Oliver Blanck, Frank-André Siebert, Alexander Fabian

• April 9, 2025

Prostate Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.

• March 3, 2025

• 1 min

Precision Oncology in Practice: How Theranostics Personalizes Treatment

In precision oncology, theranostics stands out as a transformative approach that tailors cancer treatment to the unique molecular profile of each patient. By integrating advanced diagnostic imaging with targeted therapy, theranostics ensures that treatments are customized to the unique characteristics of each patient's cancer, thereby optimizing efficacy and minimizing adverse effects.

• by

• May 11, 2025

• 4 min

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

• by

• March 15, 2026

• 21 min